Core Viewpoint - Servier and Black Diamond Therapeutics have entered into a strategic worldwide licensing agreement for BDTX-4933, a targeted therapy for solid tumors, with Servier leading its development and commercialization [1][2][6]. Group 1: Agreement Details - Servier will develop and commercialize BDTX-4933, focusing on multiple indications including non-small cell lung cancer (NSCLC) and other solid tumors [2][6]. - Black Diamond Therapeutics will receive an upfront payment of 710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales [2][6]. Group 2: Product Development - BDTX-4933 is currently in Phase 1 development, specifically designed to target RAS and RAF alterations in solid tumors [3][6]. - The ongoing first-in-human study aims to evaluate the safety, tolerability, and preliminary antitumor activity of BDTX-4933 in adults with recurrent advanced/metastatic cancers harboring specific mutations [3][6]. Group 3: Company Profiles - Servier is a global pharmaceutical group governed by a non-profit foundation, focusing on long-term innovation and reinvesting 100% of its profits into development [4][5]. - Black Diamond Therapeutics specializes in developing MasterKey therapies targeting oncogenic mutations, with a focus on addressing genetically defined tumors and overcoming treatment resistance [8].
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy